Market Cap 1.80B
Revenue (ttm) 2.20B
Net Income (ttm) -713.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 6.14
Profit Margin -32.45%
Debt to Equity Ratio 0.73
Volume 2,864,000
Avg Vol 2,658,566
Day's Range N/A - N/A
Shares Out 104.99M
Stochastic %K 22%
Beta 0.42
Analysts Sell
Price Target $20.61

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 274 4000
Address:
215 First Street, Suite 415, Cambridge, United States
Fred_Sigma_Invest
Fred_Sigma_Invest Mar. 21 at 11:06 PM
$SRPT https://www.fool.com/investing/2026/03/21/2-beaten-down-stocks-that-still-arent-worth-buying/?source=quotemedia&utm_source=marketwirenew&utm_medium=feed&utm_campaign=article&referring_guid=89aa6802-ad72-45b2-99c4-f9768d4fb723
0 · Reply
LewisDaKat
LewisDaKat Mar. 21 at 9:00 PM
$SRPT 2 Beaten-Down Stocks That Still Aren't Worth Buying https://marketwirenews.com/stock/srpt/news/2-beaten-down-stocks-that-still-aren-t-worth-buying-5363046344819305.html?utm_source=stocktwits
1 · Reply
GordonBone
GordonBone Mar. 21 at 7:25 PM
$SRPT it’s not about who might work anymore. It’s about who’s already in real patients, showing real outcomes, year after year. Sarepta isn’t a theory anymore. It’s already happening!
0 · Reply
GordonBone
GordonBone Mar. 21 at 7:16 PM
$SRPT ENDEAVOR Cohort 8 kicking off for non-amb patients with a cleaner immunosuppression setup. Feels like they actually learned from the 2025 safety issues and fixed what mattered. Non-amb is a big untapped market too. Guidance looks solid and fundamentals still there...holding tight
1 · Reply
PaixTrader
PaixTrader Mar. 21 at 7:02 PM
$SRPT This is single-dose (30/90d biopsy) vs peers DYN and RNA showing numbers largely from multi-dose cohorts. Single dose typically ≈ 50–70% of steady-state effect. So if SRPT shows: • ~25–30% , that could translate to ~40–50% with repeat dosing (competitive) • ~20–25% → gray zone (needs strong dose response) • <20% → likely behind The risk is apples-to-oranges comp vs multi-dose peer data . But what actually matters is clean dose response, consistency, and safety at higher doses. Bottom line is this readout = proof of mechanism, not peak efficacy. If biology works, numbers can scale with repeat dosing. If we clear 30% for early knockdown data for example, that would be very good. Stock initial reaction in 25-30% more tricky but should resolve nicely upwards after analysts release updated reports. If we are in the 40%+ range, we are going pie into the sky, and imo that gives very high probability to SRP1003 as best in class.
2 · Reply
nopennys
nopennys Mar. 21 at 6:31 PM
$SRPT what happened here just at market close yesterday? Huge volume?
1 · Reply
Wolfman5960
Wolfman5960 Mar. 21 at 6:12 PM
$SRPT For those waiting for the DM1 and FSHD data drop I recommend listening to the TD Cowen Conference with Ian Estepan on March 3rd (Discussion starts at the 16:45 min mark). They mentioned that data drop is still on track by the end of Q1 and Ian discusses what doses to expect from this drop at the 20:40 min mark. Looks like for DM1 it'll be the 1.5 mg/kg and 3 mg/kg data and for FSHD Ian said it will be the 1 mg/kg (I think he meant 1.5 mg/kg, but he said 1), 3 mg/kg, and 6 mg/kg . These are all from the single dose cohorts with biopsies at 30 days and 90 days.
0 · Reply
iCro93
iCro93 Mar. 21 at 3:47 PM
$SRPT we should all buy some shares at Monday open -> only on red candles. Doesn’t matter how much you buy, buy the red candles. Set an order at 100$ for the ask, the more we are the higher is the pressure on the ask once this goes parabolic with news. Just my thoughts, buy shares instead of calls.
0 · Reply
Dont_believe_pumper
Dont_believe_pumper Mar. 21 at 11:47 AM
$SRPT when will SRPT sign the deal ?? Roche, Nvidia’s 'AI Factory' The AI race in biopharma is heating up. Roche and Nvidia partnered on what they’re calling the "largest announced hybrid-cloud AI factory" in the industry. The announcement comes just a few months after Eli Lilly unveiled plans for its own AI-powered supercomputer, which Lilly claimed would be biopharma’s most powerful. Roche’s Genentech originally signed a deal with Nvidia in 2023. The newly expanded agreement covers the broader Roche enterprise, spanning its drugs and diagnostics businesses and areas like discovery, manufacturing and sales. The computing power will be used to train and run AI models across those functions. On the hardware side, Roche is adding 2,716 of Nvidia's Blackwell GPUs, bringing its total to over 3,500 Blackwell chips — compared with the 1,016 chips in Lilly's supercomputer. Biopharma industry looks to soften MFN i
1 · Reply
GhostInTheStocks
GhostInTheStocks Mar. 21 at 11:03 AM
$SRPT if you are panic selling your shares during the large dips these past six months, it is likely that some of them are ending up in blackrock or vanguard hands. They have been the biggest dip buyers, blackrock being the more agressive buyer.
0 · Reply
Latest News on SRPT
Sarepta CEO To Jump Ship After 'Tumultuous' Year

Feb 26, 2026, 5:52 AM EST - 23 days ago

Sarepta CEO To Jump Ship After 'Tumultuous' Year


Sarepta Therapeutics CEO Ingram to retire by year end

Feb 26, 2026, 5:05 AM EST - 23 days ago

Sarepta Therapeutics CEO Ingram to retire by year end


Sarepta Therapeutics: Is Elevidys A Bust?

Jan 16, 2026, 9:25 AM EST - 2 months ago

Sarepta Therapeutics: Is Elevidys A Bust?


Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Nov 14, 2025, 5:48 PM EST - 4 months ago

Sarepta Shares Jump After FDA Approves Updated Elevidys Label


Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Nov 4, 2025, 12:11 PM EST - 4 months ago

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It


Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:24 PM EST - 4 months ago

Sarepta's Duchenne gene therapy misses main goal in study


What's Going On Sarepta Stock On Wednesday?

Oct 8, 2025, 11:19 AM EDT - 5 months ago

What's Going On Sarepta Stock On Wednesday?


Fred_Sigma_Invest
Fred_Sigma_Invest Mar. 21 at 11:06 PM
$SRPT https://www.fool.com/investing/2026/03/21/2-beaten-down-stocks-that-still-arent-worth-buying/?source=quotemedia&utm_source=marketwirenew&utm_medium=feed&utm_campaign=article&referring_guid=89aa6802-ad72-45b2-99c4-f9768d4fb723
0 · Reply
LewisDaKat
LewisDaKat Mar. 21 at 9:00 PM
$SRPT 2 Beaten-Down Stocks That Still Aren't Worth Buying https://marketwirenews.com/stock/srpt/news/2-beaten-down-stocks-that-still-aren-t-worth-buying-5363046344819305.html?utm_source=stocktwits
1 · Reply
GordonBone
GordonBone Mar. 21 at 7:25 PM
$SRPT it’s not about who might work anymore. It’s about who’s already in real patients, showing real outcomes, year after year. Sarepta isn’t a theory anymore. It’s already happening!
0 · Reply
GordonBone
GordonBone Mar. 21 at 7:16 PM
$SRPT ENDEAVOR Cohort 8 kicking off for non-amb patients with a cleaner immunosuppression setup. Feels like they actually learned from the 2025 safety issues and fixed what mattered. Non-amb is a big untapped market too. Guidance looks solid and fundamentals still there...holding tight
1 · Reply
PaixTrader
PaixTrader Mar. 21 at 7:02 PM
$SRPT This is single-dose (30/90d biopsy) vs peers DYN and RNA showing numbers largely from multi-dose cohorts. Single dose typically ≈ 50–70% of steady-state effect. So if SRPT shows: • ~25–30% , that could translate to ~40–50% with repeat dosing (competitive) • ~20–25% → gray zone (needs strong dose response) • <20% → likely behind The risk is apples-to-oranges comp vs multi-dose peer data . But what actually matters is clean dose response, consistency, and safety at higher doses. Bottom line is this readout = proof of mechanism, not peak efficacy. If biology works, numbers can scale with repeat dosing. If we clear 30% for early knockdown data for example, that would be very good. Stock initial reaction in 25-30% more tricky but should resolve nicely upwards after analysts release updated reports. If we are in the 40%+ range, we are going pie into the sky, and imo that gives very high probability to SRP1003 as best in class.
2 · Reply
nopennys
nopennys Mar. 21 at 6:31 PM
$SRPT what happened here just at market close yesterday? Huge volume?
1 · Reply
Wolfman5960
Wolfman5960 Mar. 21 at 6:12 PM
$SRPT For those waiting for the DM1 and FSHD data drop I recommend listening to the TD Cowen Conference with Ian Estepan on March 3rd (Discussion starts at the 16:45 min mark). They mentioned that data drop is still on track by the end of Q1 and Ian discusses what doses to expect from this drop at the 20:40 min mark. Looks like for DM1 it'll be the 1.5 mg/kg and 3 mg/kg data and for FSHD Ian said it will be the 1 mg/kg (I think he meant 1.5 mg/kg, but he said 1), 3 mg/kg, and 6 mg/kg . These are all from the single dose cohorts with biopsies at 30 days and 90 days.
0 · Reply
iCro93
iCro93 Mar. 21 at 3:47 PM
$SRPT we should all buy some shares at Monday open -> only on red candles. Doesn’t matter how much you buy, buy the red candles. Set an order at 100$ for the ask, the more we are the higher is the pressure on the ask once this goes parabolic with news. Just my thoughts, buy shares instead of calls.
0 · Reply
Dont_believe_pumper
Dont_believe_pumper Mar. 21 at 11:47 AM
$SRPT when will SRPT sign the deal ?? Roche, Nvidia’s 'AI Factory' The AI race in biopharma is heating up. Roche and Nvidia partnered on what they’re calling the "largest announced hybrid-cloud AI factory" in the industry. The announcement comes just a few months after Eli Lilly unveiled plans for its own AI-powered supercomputer, which Lilly claimed would be biopharma’s most powerful. Roche’s Genentech originally signed a deal with Nvidia in 2023. The newly expanded agreement covers the broader Roche enterprise, spanning its drugs and diagnostics businesses and areas like discovery, manufacturing and sales. The computing power will be used to train and run AI models across those functions. On the hardware side, Roche is adding 2,716 of Nvidia's Blackwell GPUs, bringing its total to over 3,500 Blackwell chips — compared with the 1,016 chips in Lilly's supercomputer. Biopharma industry looks to soften MFN i
1 · Reply
GhostInTheStocks
GhostInTheStocks Mar. 21 at 11:03 AM
$SRPT if you are panic selling your shares during the large dips these past six months, it is likely that some of them are ending up in blackrock or vanguard hands. They have been the biggest dip buyers, blackrock being the more agressive buyer.
0 · Reply
HuanLee
HuanLee Mar. 21 at 7:21 AM
$SRPT Not just a drug… this is a whole modality shift playing out in real time
0 · Reply
HillA
HillA Mar. 21 at 6:11 AM
$SRPT Every update = more validation the science works. That’s what matters long term.
0 · Reply
iceicemoney10
iceicemoney10 Mar. 21 at 4:24 AM
$SRPT gentleman, I don’t know any of you fellow bulls. I’m hammered at the club. I feel like we are all a brotherhood, fighting in the trenches together. We will prevail. Keep fighting the good fight. We will beat AF and the shorts and these families will get the treatments they deserve!!
0 · Reply
iceicemoney10
iceicemoney10 Mar. 21 at 3:47 AM
$SRPT Monday. We are rich gentleman. Enjoy the weekend. Get ready to print Monday fellas
1 · Reply
Thaigrlsrk
Thaigrlsrk Mar. 21 at 12:12 AM
$SRPT People act like it's an automatic thing RGNX or SLDB drugs will be better. It ain't. It is as likely they will have deaths as it is/was for Sarepta. Sarepta has in people data out to six years they only have very short time data and even that is questionably comparable. Long way to go to prove either.
0 · Reply
Thaigrlsrk
Thaigrlsrk Mar. 20 at 11:28 PM
$SRPT AF says ( and some others ) that the PMo's are just placebos. Billy one of the original 12 kids in the Etep( exon 51) trial is now in his 20's been on Etep for more then 10 years, he decided against Elevidys( nuts IMO but who am i to say) because he was happy with how he has held up on the PMO. FK AF and all those guys that bet against it's approval and lost . They lost because there is BENEFIT. EOS. He should interview people like Billy instead of running his mouth against the rare disease kids.
0 · Reply
DM73
DM73 Mar. 20 at 11:21 PM
$SRPT you thinking weekend / Monday?
2 · Reply
DM73
DM73 Mar. 20 at 11:20 PM
$SRPT when you thinking? Monday ?
1 · Reply
Thaigrlsrk
Thaigrlsrk Mar. 20 at 10:36 PM
$SRPT By the end of June Sarepta will surpass ARWR in SP. Good Dm1/FSHD data, completed dosing in sirolimus trial. Acceptance of NDA for PMO's If we get a raise in projected revenues could go higher.
1 · Reply
PaixTrader
PaixTrader Mar. 20 at 8:48 PM
$SRPT mgmt sandbagged expectations for the initial read, repeatedly guiding the market to focus on PK and dose-response. That framing may have been more FSHD-specific than DM1, but the takeaway is the same: the bar is low. If SRP-1003 prints solid data—inline or better vs early Avidity Biosciences / Dyne Therapeutics—this likely gets a strong reaction. No idea what the data holds (I hope beats expectations). But the Setup is there.
1 · Reply
PaixTrader
PaixTrader Mar. 20 at 8:30 PM
$SRPT fyi, don’t be suprised if DM1 data just drops without warning. Would Be the best move if very bullish. Creates Maximum surprise = maximum move, less expectation risk, less front running, etc. just one shock to everyone which causes shorts to cover and others to chase.
3 · Reply
iCro93
iCro93 Mar. 20 at 8:07 PM
$SRPT 1 million volume last 10 min. 50% of the day volume. Insane
0 · Reply